A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Felmetatug vedotin’s exit could be bad news for Mersana.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
AstraZeneca bags three of the month’s four oncology approvals.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
